Bracco Secures FDA and Health Canada Clearance for VueJect Cardiovascular Ultrasound System
Event summary
- Bracco's VueJect®, a dedicated ultrasound contrast delivery system for cardiology imaging, received FDA 510(k) clearance and Health Canada authorization on August 11, 2026.
- VueJect aims to improve workflow efficiency, reduce operator variability, and enable continuous administration of contrast agents in cardiac imaging procedures.
- The system will initially launch in the U.S. and Canada, with plans for regulatory submissions in additional global markets.
- Bracco positions VueJect as a key addition to its contrast-enhanced ultrasound (CEUS) ecosystem.
The big picture
Bracco's FDA and Health Canada clearances for VueJect mark a strategic milestone in its push to dominate the contrast-enhanced ultrasound (CEUS) market. The system aligns with broader industry trends toward precision diagnostics and workflow efficiency, particularly in cardiovascular imaging. With €2 billion in annual revenues and 9% of turnover invested in R&D, Bracco is positioning itself as a leader in advanced diagnostic solutions.
What we're watching
- Market Expansion
- The pace at which Bracco secures regulatory approvals in additional markets will determine VueJect's global reach and revenue potential.
- Competitive Positioning
- Whether VueJect can differentiate itself in a market dominated by established ultrasound contrast delivery systems.
- Clinical Adoption
- How quickly cardiac sonographers and physicians integrate VueJect into their workflows, impacting its adoption rate.
Related topics